Eilidh Mcginnigle: Hello, and thank you for joining us for this Cardiovascular Research Onlife interview with Professor Marian. My name is Eilidh Mcginnigle, and I am a cardiology registrar here in the West of Scotland.
Professor Marian is over visiting from Texas and we look forward to hearing some of his insights. So, Professor Marian, as a clinician who works in science and in translational research-how important do you feel it is for clinicians to work in pre-clinical sciences?
Ali J. Marian: My personal view is that every physician should train as a scientist during his or her medical school years and afterwards; a sub-group of those physicians that pursue science will be the group that will make the next phase of discoveries that will impact the clinical care of patients.
I strongly believe that physician-scientists are an essential component of today's biomedical society, and a group that will certainly advance the science and practice of medicine to the next level. So, very crucial.
Eilidh Mcginnigle In recent work that's been done in genetic cardiomyopathies, what do you feel are the big players that are emerging at the moment?
Ali J. Marian: So, genetics to me is the fundamentals, and basically the essence of all human diseases. Understanding the fundamental basis of a human disease is a crucial step in trying to find the mechanisms that are involved in its pathogenesis, and subsequently to intervene-targeting those mechanistic pathways to prevent, attenuate, or cure the disease.
In cardiomyopathies, the first discovery of a genetic mutation in 1990s by Cricket and John Seidman from Harvard University (Cambridge, MA, USA) paved the way to delineation of the mechanisms by which actin and myosin interact. From this, we learned that interaction of myosin and actin is a fundamental mechanism in the pathogenesis of cardiomyopathy.
Subsequently, the investigators have moved on and developed drugs that can target this specific mechanism, and it is hoped that by targeting this, we should be able to, perhaps partially at least, treat hypertrophic cardiomyopathy for which currently there is no effective pharmacological therapy.
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